Consulting agreement under which Dr. Pepose was paid a monthly consulting fee and received 32,000 RSUs and options to purchase 48,000 shares; the Company incurred related consulting expenses in fiscal year 2025
| Officer | Age | In this role | 2025 pay | Source |
|---|---|---|---|---|
|
George Magrath
Also a director
Chief Executive Officer
|
42 | Not stated | $1,493,383 | |
|
Robert Gagnon
Chief Financial Officer
|
51 |
Since 2025
1 year
|
Not reported | |
|
Benjamin R. Yerxa
Also a director
President
|
60 | Not stated | Not reported | |
|
Joseph Schachle
Chief Operating Officer
|
61 |
Since 2023
3 years
|
$718,408 | |
|
Ashwath Jayagopal
Chief Scientific & Dev. Ofc.
Title from the Form 4 dated Apr 23, 2026
|
44 | Not stated | $764,848 | |
|
Amy Rabourn
Head of Fin. Quality Assurance
Title from the Form 4 dated Apr 23, 2026
|
46 | Not stated | Not reported |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Consulting agreement under which Dr. Pepose was paid a monthly consulting fee and received 32,000 RSUs and options to purchase 48,000 shares; the Company incurred related consulting expenses in fiscal year 2025
Subscription agreement to purchase 392,157 shares of Common Stock and receive 392,157 warrants in a private offering
Subscription agreement to purchase 784,314 shares of Common Stock and receive 784,314 warrants in a private offering
Investment of $1.0 million in the August 2025 Private Placement
Participation in the August 2025 Private Placement with an investment of $0.1 million
2022 binding letter agreement to collaborate on natural history studies, requiring the Company to provide a total of $2.0 million of funding, superseded in 2025
2025 letter agreement to collaborate on a study of retinal dystrophies; the Company paid $0.3 million in fiscal year 2025 and must fund one more installment of $0.3 million
Funding agreement providing nondilutive funding of up to $2.0 million for the MERTK Program, with $1.0 million disbursed in June 2025, and royalty and milestone payment obligations to RDF
Loading...